Regeneron Pharmaceuticals expects a U.S. decision on a higher-dose version of its blockbuster eye disease drug Eylea in the third quarter, much earlier than market expectations, sending its shares 5% higher in premarket trading on Thursday.
U.S. sales of Eylea fell 7% to $1.50 billion in the second quarter, but came in slightly above estimates of $1.48 billion., surged 33% to $2.79 billion during the quarter. Sales of the treatment, which was approved in 2017, has helped mitigate the decline in sales of Eylea.
Regeneron reported adjusted profit of $10.24 per share for the second quarter, topping analysts' average estimates of $9.84, according to Refinitiv data.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Regeneron’s stock rallies after profit, revenue rise above expectations, amid a jump in collaboration revenueShares of Regeneron Pharmaceuticals Inc. climbed 2.6% toward a 5-week high in premarket trading Thursday, after the biotechnology company reported...
Read more »
FDA, DEA call on drugmakers to boost manufacturing amid ongoing shortage of prescription stimulants | CNNAmid an ongoing shortage of prescription stimulants in the US, federal agencies are calling on drugmakers to boost manufacturing and on health care providers to closely monitor prescribing practices.
Read more »
Thousands of Tydemy birth control pills recalled, may be ineffective, FDA warnsA drugmaker recalled thousands of birth control pills after testing found they might have lower effectiveness.
Read more »
FDA, DEA Blame Demand, Drug Makers for ADHD Med ShortageIn a letter to the public the FDA and the DEA contend that unprecedented demand, potential overprescribing, and underproduction are the primary reasons for the national shortage of stimulants to treat ADHD.
Read more »
Thousands of birth control pills recalled, may be ineffective, FDA warnsA total of 4,179 boxes of Tydemy brand birth control pills have been recalled, which amounts to about 350,000 tablets that might be less effective at stopping pregnancy.
Read more »
FDA warns that some lots of Tydemy birth control pill may be ineffectiveThe Food and Drug Administration said Tuesday that two lots of birth-control pill Tydemy, made by privately held Lupin Pharmaceuticals, “may have reduced...
Read more »